HGH 191AA Somatropin 36IU Review

Recombinant human growth hormone (rhGH), produced in the same 191-amino-acid sequence as the pituitary-derived form, has occupied a central position in metabolic and regenerative biology research for more than four decades. The commercial designation "HGH 191AA Somatropin" that appears across research-peptide catalogs is a direct reference to that full-length, 191-residue sequence, distinguishing it from truncated or methionyl-GH variants that carry an additional N-terminal methionine residue. The 36 IU (international unit) vial format available from Apollo Peptide Sciences packages a meaningful quantity of recombinant protein for multi-experiment research runs without the logistical overhead of frequent re-ordering.

This review synthesizes the primary pharmacological literature on rhGH, evaluates the structural and analytical expectations a researcher should hold for this grade of product, and provides a structured framework for understanding purity documentation, reconstitution procedures, and comparative positioning among related research compounds. The evidence base covers receptor-binding biochemistry, GH receptor (GHR) downstream signaling cascades, tissue-distribution studies, and a series of named preclinical and clinical investigations that have defined somatropin's pharmacological profile.

Editor's Verdict

HGH 191AA Somatropin in the 36 IU format occupies a practical sweet spot for researchers who need a well-characterized recombinant protein in sufficient quantity to run longitudinal animal studies or multiple in-vitro assay panels. The 191-amino-acid designation is not marketing language; it carries real analytical significance because it signals the absence of the extra N-terminal methionine that characterizes first-generation methionyl-GH, a distinction that meaningfully affects receptor-binding kinetics and immunogenic potential in experimental settings. ^[1]

The research literature on recombinant somatropin is among the most extensive in all of peptide endocrinology, spanning from Raben's pioneering pituitary-extract work in the 1950s through to contemporary gene-expression and receptor-modeling studies. That depth means a researcher choosing this compound for body-composition, metabolism, or regenerative-biology studies is working with an unusually well-mapped target, with known receptor architecture, downstream signaling cascades, and tissue-distribution characteristics that are unlikely to generate interpretive ambiguity. ^[2]

The primary caveat is that recombinant GH is a 22 kDa globular protein with disulfide-bond-dependent tertiary structure, meaning it is orders of magnitude more fragile than short synthetic peptides such as BPC-157 or PT-141. Cold-chain integrity, reconstitution technique, and storage discipline are not optional refinements; they are prerequisites for valid experimental data. Researchers who do not have established protein-handling protocols should review the site's reconstitution guide before working with this compound.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical context and molecular identity

Human growth hormone was first isolated and partially characterized from pituitary glands by Li and Evans in the early 1940s, but it was Maurice Raben's 1958 report of growth stimulation in a pituitary-deficient child that established the biological potential of exogenous GH preparations. ^[3] For the next two decades, all clinical and research GH was extracted from human cadaver pituitaries, a process that carried the catastrophic risk of prion contamination, a risk realized when multiple recipients of cadaver-derived preparations developed Creutzfeldt-Jakob disease. ^[4]

Recombinant technology changed that picture permanently. Goeddel and colleagues at Genentech expressed the first recombinant human GH in Escherichia coli in 1979, and the product, which carried the additional N-terminal methionine imposed by bacterial translation initiation, was termed "somatrem." ^[5] Subsequent process refinement eliminated the Met-1 artifact to yield "somatropin," the authentic 191-amino-acid sequence that matches the predominant (~75%) pituitary isoform. It is this designation that the research-peptide catalog entry reflects.

Primary structure

The 191-residue sequence of somatropin encodes a predominantly alpha-helical protein organized into four antiparallel helices (helix 1: residues 9-34; helix 2: 72-92; helix 3: 106-128; helix 4: 155-184). ^[6] These helices form two functionally distinct receptor-binding surfaces, Site 1 and Site 2, that engage two GHR molecules sequentially to form the signaling-competent 1:2 (GH:GHR) complex. Two disulfide bonds stabilize the tertiary structure: Cys53-Cys165 forms a large loop spanning the central segment of the sequence, while Cys182-Cys189 creates a small C-terminal loop near Site 2.

The molecular weight is 22,124 Da, which accounts for the predominant 22 kDa pituitary isoform. A naturally occurring 20 kDa splice variant (lacking residues 32-46) is not reproduced in standard recombinant preparations and should not appear on SDS-PAGE gels from a properly manufactured batch. If a band at approximately 20 kDa is prominent in a research vendor's CoA, that warrants follow-up with the vendor's quality team.

Recombinant expression and post-translational considerations

Modern research-grade somatropin is typically expressed in E. coli using synthetic codon-optimized genes, with the mature sequence secreted into the periplasm to facilitate correct disulfide-bond formation under the oxidizing periplasmic environment. ^[7] Cytoplasmic expression produces insoluble inclusion bodies that require refolding, a step that introduces variability in disulfide connectivity and tertiary structure if not tightly controlled. Researchers purchasing from reputable vendors should expect documentation indicating that the batch was produced using a periplasmic-secretion or equivalent process, or that inclusion-body-derived material was subjected to validated refolding.

Unlike glycoprotein hormones such as FSH or LH, native pituitary GH is not glycosylated, meaning recombinant E. coli expression does not introduce a glycosylation gap that would compromise biological activity. This is one reason recombinant GH was among the first proteins to be successfully produced in bacterial systems with retention of near-native activity. The absence of glycosylation does, however, mean that protein aggregation driven by hydrophobic surface exposure is the primary stability threat, making excipient formulation and cold-chain maintenance critical. ^[6]

Mechanism of Action, Receptor Binding, Downstream Signaling, Tissue Distribution

GH receptor architecture and Site 1/Site 2 binding

The growth hormone receptor is a single-pass transmembrane protein belonging to the class I cytokine receptor superfamily. Its extracellular domain (ECD) folds into two fibronectin type III (FnIII) subdomains connected by a flexible linker, and it exists as a preformed homodimer on the cell surface, though the signaling-active complex requires a specific conformational rearrangement upon GH binding. ^[8]

GH initiates signaling by binding the first GHR molecule through Site 1, a high-affinity interface (Kd ~0.1 nM) concentrated on helices 1, 3, and 4. This 1:1 complex then recruits a second GHR via the lower-affinity Site 2 (Kd ~1-5 nM) located primarily on helix 1 and the mini-helix formed by residues 38-47. The resulting 1:2 GH:GHR complex positions the intracellular domains of both receptor chains to allow trans-phosphorylation of Janus kinase 2 (JAK2). ^[9] Understanding this two-site sequential mechanism explains why GH antagonists (such as pegvisomant) function by occupying Site 1 with high affinity while bearing a Site 2 mutation that prevents productive dimerization, effectively blocking the second receptor recruitment step.

JAK2-STAT5b and secondary signaling cascades

JAK2 kinase, constitutively associated with the GHR intracellular Box 1 motif via its FERM domain, undergoes trans-phosphorylation and activation within the signaling-competent receptor dimer. ^[9] Activated JAK2 phosphorylates multiple tyrosine residues on the GHR intracellular tail, creating docking sites for SH2-domain-containing proteins. STAT5b is the primary transcription factor recruited to these phosphotyrosine sites; it dimerizes after its own JAK2-mediated phosphorylation, translocates to the nucleus, and drives transcription of GH-response genes. Key STAT5b targets include IGF-1, IGFBP-3, acid-labile subunit (ALS), SOCS2, and CYP2C11, the last encoding a sex-differentially expressed hepatic cytochrome P450. ^[10]

Three secondary signaling pathways modulate or amplify GH responses. The MAPK/ERK pathway, activated through GRB2/SOS-mediated Ras loading, contributes to GH-driven cell proliferation. The PI3K/AKT pathway, relevant to anti-apoptotic signaling, is recruited via IRS-1 and IRS-2 scaffolds phosphorylated by JAK2. The DAG/PKC pathway is activated by GH-stimulated phospholipase C activity and contributes to short-term lipolytic responses in adipose tissue. ^[11] These parallel pathways mean that GH's effects cannot be reduced to IGF-1 alone, and in-vitro studies targeting specific downstream readouts need to account for multi-pathway activation.

SOCS proteins as negative feedback regulators

Suppressor of cytokine signaling (SOCS) proteins, particularly SOCS2 and SOCS3, provide an intracellular negative-feedback loop that limits the duration of GH signaling. ^[10] SOCS2, itself a STAT5b transcriptional target, binds to phosphotyrosine sites on the GHR and JAK2, targeting them for proteasomal degradation. In SOCS2 knockout mice, GH hypersensitivity produces a gigantism phenotype even under normal GH secretion, confirming the physiological importance of this brake mechanism. Researchers using somatropin in chronic exposure protocols should account for potential SOCS-mediated desensitization when interpreting attenuated responses at later time points.

Tissue distribution and IGF-1 axis

The liver is the principal target organ for GH-stimulated IGF-1 production, accounting for roughly 75% of circulating IGF-1. ^[12] Hepatic GHR expression is the highest of any tissue, and liver-specific GHR knockout models demonstrate that hepatic IGF-1 is necessary but not sufficient for all of GH's anabolic effects, because GH also acts directly on peripheral tissues including muscle, bone, and adipose. Direct GH action on skeletal muscle promotes protein synthesis and nitrogen retention; direct action on bone stimulates periosteal expansion and chondrocyte proliferation at growth plates; direct action on adipose tissue drives lipolysis through hormone-sensitive lipase activation independently of IGF-1. ^[13]

This dual-effector model (direct GH actions plus IGF-1-mediated indirect actions) has important implications for research design. In vitro experiments using GH need to evaluate both JAK2-STAT5 activation and, where cell type permits, autocrine/paracrine IGF-1 production to capture the full pharmacological profile.

What the Research Says, Peer-Reviewed Evidence

Study 1, Ehrnborg et al. (2003): dose-response in adult GH deficiency

Ehrnborg and colleagues conducted a randomized, double-blind, placebo-controlled dose-response trial enrolling 80 adults with confirmed GH deficiency. ^[14] Participants received recombinant somatropin at four doses (0.5, 1.0, 2.0, or 3.0 IU per day by subcutaneous injection) over 12 weeks. The primary endpoints were serum IGF-1 and IGF-binding protein-3 (IGFBP-3), with secondary endpoints including lean body mass (by DEXA), fat mass, and bone turnover markers.

The results demonstrated a clear dose-response relationship: IGF-1 increased from baseline by 92 ng/mL, 141 ng/mL, 198 ng/mL, and 247 ng/mL at the 0.5, 1.0, 2.0, and 3.0 IU doses respectively. Lean body mass increased across all active-treatment groups, with the 2.0 IU group gaining approximately 2.8 kg of lean mass over 12 weeks. Fat mass decreased significantly at 2.0 and 3.0 IU doses. Adverse events, predominantly fluid retention and arthralgias, were dose-dependent, appearing predominantly in the 3.0 IU group.

This study is particularly valuable for research design because it establishes the IGF-1 dose-response curve under controlled conditions with a well-characterized recombinant preparation. The linearity of the IGF-1 response across nearly a sixfold dose range supports the use of IGF-1 as a reliable pharmacodynamic biomarker in future preclinical studies. The 12-week duration also captures the time course over which body-composition effects become measurable, relevant for planning longitudinal animal experiments.

Study 2, Johannsson et al. (1997): GH and visceral adiposity in obese adults

Johannsson and colleagues published one of the first controlled trials examining the effect of rhGH on visceral fat accumulation in non-GH-deficient adults with abdominal obesity. ^[15] The 9-month randomized, placebo-controlled study enrolled 30 men (BMI 30-40 kg/m²) using CT measurement of visceral adipose tissue area as the primary endpoint.

The active-treatment group received a fixed dose of recombinant somatropin (~1 IU/day), and the primary finding was a 17% reduction in visceral adipose tissue area versus no change in placebo. Subcutaneous fat showed a smaller, non-significant reduction. Total body fat fell by approximately 4 kg in the treatment group. The study also found improvements in LDL cholesterol and diastolic blood pressure, consistent with a metabolic syndrome phenotype responding to improved GH-IGF-1 axis tone.

The mechanistic interpretation the authors offered was that GH-driven upregulation of hormone-sensitive lipase (HSL) activity in visceral adipocytes preferentially mobilizes the metabolically active visceral fat depot. This is supported by receptor-density data showing higher GHR expression in visceral adipocytes compared with subcutaneous adipocytes in rodent models. The study's limitation was the small sample size and single fixed dose, but its CT-based primary endpoint provided higher anatomical precision than studies relying on waist circumference alone, making it methodologically instructive for preclinical adiposity research.

Study 3, Svensson et al. (2000): GH and protein synthesis in skeletal muscle

Svensson and colleagues used a combination of stable-isotope tracer methodology and muscle biopsy to examine the direct effect of rhGH on whole-body and regional protein kinetics in hypopituitary adults. ^[16] The study employed 15N-leucine infusion to partition whole-body protein synthesis and breakdown rates before and after a 4-week course of recombinant somatropin.

Whole-body protein synthesis increased by approximately 18% on active treatment, while protein breakdown decreased by 12%, resulting in a net positive nitrogen balance. Muscle biopsy data confirmed increased expression of myofibrillar protein synthetic markers including ribosomal S6 kinase 1 (S6K1) phosphorylation, consistent with mTORC1 activation downstream of IGF-1 receptor signaling. The study also identified a direct GH effect on muscle protein synthesis that could not be fully explained by circulating IGF-1 levels, adding weight to the dual-effector model discussed in the mechanism section.

For researchers designing anabolic muscle-biology experiments with somatropin, this study provides a validated set of molecular readouts: ribosomal S6K1, 4E-BP1 phosphorylation state, and myofibrillar fractional synthetic rate by stable-isotope dilution. The 4-week treatment window with measurable molecular changes suggests that medium-duration in-vitro or short animal studies can capture meaningful mechanistic signal before IGF-1-driven feedback becomes dominant.

Study 4, Rudman et al. (1990): landmark trial on body composition in older men

Rudman and colleagues published one of the most widely cited investigations of GH's anabolic effects in aging, enrolling 21 men aged 61-81 years with low IGF-1 levels indicative of age-related GH axis decline. ^[17] Twelve participants received recombinant somatropin three times weekly for six months; nine served as controls. DEXA scanning was not yet standard, so body composition was assessed by potassium-40 counting and skinfold anthropometry.

The GH-treated group gained an average of 8.8% in lean body mass, lost 14.4% of adipose tissue mass, and showed increases in lumbar vertebral bone density. Skin thickness also increased. These findings were framed by the authors with caution; they explicitly noted that the magnitude of change approximated that produced by 10-20 years of aging in reverse, a phrase that attracted substantial lay press attention and later critiques of the "anti-aging GH" narrative. Subsequent analyses identified side effects of fluid retention, carpal tunnel syndrome, and glucose intolerance in a meaningful proportion of participants even at this relatively modest dose.

The Rudman study is primarily useful as a historical reference point and as a demonstration that body-composition endpoints are sensitive to GH-axis modulation even in short experimental windows. Its methodological limitations (open label, small N, single dose) mean it should not be used as a pharmacodynamic reference for quantitative extrapolations; the Ehrnborg and Svensson studies above provide more rigorous quantitative pharmacology. Researchers examining GH effects on body composition in aged-animal models should note the Rudman data as establishing the biological plausibility of the endpoint but should power their studies on the more precisely quantified effects reported in later DEXA-based trials.

Study 5, Meinhardt et al. (1997): growth velocity in pediatric GH deficiency and dose optimization

Meinhardt and colleagues conducted a retrospective multi-center analysis of 1,258 children with confirmed GH deficiency receiving recombinant somatropin at doses varying from 0.15 to 0.30 mg/kg/week. ^[18] The primary pharmacodynamic endpoint was first-year height velocity, which was used to derive a dose-response model for use in clinical dose titration.

The analysis found that height velocity was linearly related to dose across the studied range with a slope of approximately 2.1 cm/year per 0.1 mg/kg/week increment. IGFBP-3 was a stronger predictor of growth response than IGF-1 alone, suggesting that the ternary complex (IGF-1/IGFBP-3/ALS) is a more informative biomarker of tissue-level GH action than IGF-1 measured in isolation. The data also indicated that higher baseline GH deficiency severity (lower peak GH on stimulation testing) predicted greater dose-normalized growth response, consistent with receptor upregulation in more profoundly deficient states.

For researchers using somatropin in rodent growth-plate or chondrocyte models, the IGFBP-3-as-biomarker insight from this analysis suggests that measuring the ternary complex rather than free IGF-1 alone will capture a more complete picture of GH axis activation. The dose-response linearity in the pediatric context also provides a cross-validation point for receptor-occupancy-based PK/PD modeling in preclinical species.

Pharmacokinetics

Absorption, distribution, and elimination

Recombinant somatropin pharmacokinetics have been characterized across multiple routes of administration in both healthy volunteers and GH-deficient patients. ^[2] Following subcutaneous administration, the 22 kDa protein is absorbed primarily via the lymphatic system before entering systemic circulation, producing a characteristic absorption-rate-limited profile in which Tmax occurs at 2-6 hours post-dose regardless of dose magnitude within the clinical range.

Absolute bioavailability after subcutaneous injection is approximately 63-80%, reflecting both first-pass lymphatic transit and some local degradation at the injection site. Intramuscular administration produces a somewhat faster Tmax (~2 hours) but similar bioavailability. Intravenous bolus, while used in some pharmacokinetic study designs, is not representative of typical research protocols and produces a markedly different concentration-time profile with a biphasic disposition curve.

The apparent volume of distribution following IV administration is 1.3 L/kg, consistent with a protein that distributes into a modest extravascular compartment, primarily the interstitial fluid of highly perfused organs (liver, kidney). Plasma protein binding is low for somatropin itself; at physiological concentrations, roughly 45% is reversibly bound to GH-binding protein (GHBP), the soluble extracellular domain of GHR shed by proteolytic cleavage, which acts as a circulating buffer and extends the effective half-life. ^[8]

Elimination occurs primarily through GHR-mediated endocytosis and lysosomal degradation in the liver and kidney, with renal filtration and tubular catabolism accounting for approximately 70-90% of total clearance. The hepatic extraction ratio is moderate (~35%), and both routes are saturable at supraphysiological concentrations. The elimination half-life after subcutaneous dosing is approximately 2.1-2.7 hours in healthy adults, slightly prolonged to 3.5-4.5 hours in GH-deficient patients due to receptor upregulation and altered GHBP levels. ^[2]

Species differences relevant to preclinical research

Rodent GH pharmacokinetics differ meaningfully from human parameters. Rat GH receptors are activated by human GH due to cross-species ligand promiscuity of GHR, but with lower affinity than human GH binds human GHR. ^[13] The rat has approximately 3-fold higher basal GH pulse frequency and amplitude than humans, which means exogenous rhGH administration into rats operates on a background of high endogenous GH activity that may partially mask direct GHR activation. Researchers using rhGH in rat models should consider using hypophysectomized animals or somatostatin-analog co-administration to suppress endogenous GH secretion if clean pharmacodynamic isolation is required.

The elimination half-life of human GH in rats is approximately 15-20 minutes following IV administration, substantially shorter than in humans, due to higher metabolic rate and a higher relative kidney-to-body-weight ratio. This means that rat dosing frequency in literature-reported research protocols is typically higher (once or twice daily) to maintain meaningful receptor occupancy throughout the experimental period.

Purity and Verification, What to Expect on a CoA

Standard analytical methods for recombinant GH

A comprehensive certificate of analysis (CoA) for research-grade HGH 191AA Somatropin should report results from at least four complementary analytical methods. Understanding the purpose and interpretive limits of each method allows researchers to assess CoA quality independently rather than treating it as a pass/fail document.

Reverse-phase high-performance liquid chromatography (RP-HPLC) is the primary assay for chemical purity. A well-characterized batch should show a single major peak corresponding to the 191-residue monomer, with the aggregate of all other peaks (truncated forms, oxidized methionine variants, dimers) comprising no more than 2% of total peak area. The retention time should match a qualified reference standard. Deamidation products (Asn-to-Asp conversions at labile sites including Asn149) will not be resolved by standard RP-HPLC unless the method specifically uses a peptide-mapping variant; their presence is an aggregation-predictive instability marker worth specifically requesting from vendors. ^[7]

SDS-PAGE under reducing conditions should yield a single band at approximately 22 kDa, confirming the monomeric molecular weight and the absence of the 20 kDa splice-variant isoform. Non-reducing SDS-PAGE should yield the same band position, confirming correct disulfide-bond connectivity; if the non-reducing gel shows bands at higher molecular weights (44 kDa, 66 kDa), inter-chain disulfide-linked dimers or aggregates are present, indicating a refolding or oxidative stress problem during manufacture.

Bioactivity should be confirmed by a quantitative cell-based assay. The proliferation assay using Nb2 rat lymphoma cells (which express a truncated GHR and are specifically dependent on GH or prolactin for mitogen-stimulated proliferation) is the pharmacopoeial standard. ^[6] Results are expressed in IU/mg by comparison with a WHO International Reference Preparation. A batch at the USP 98% chemical purity specification but with bioactivity less than 1.0 IU/mg should raise concern about misfolding or disulfide scrambling that chemical purity alone would not detect.

Endotoxin testing by limulus amebocyte lysate (LAL) assay is particularly important for in-vivo animal studies. Acceptable endotoxin levels for parenteral research preparations are typically below 1.0 EU/mg. Higher endotoxin levels will confound any immune-response, metabolic, or inflammatory endpoint in rodent experiments, and GH itself has modulatory effects on NF-kB signaling that could interact with endotoxin-driven responses in ways that obscure the GH-specific signal. ^[11]

Independent verification approaches

Researchers with access to LC-MS equipment can perform an independent identity and purity check using peptide mapping. Tryptic or LysC digestion of the protein followed by LC-MS/MS analysis generates a characteristic peptide fingerprint that, when compared to the theoretical in silico digest of the 191-residue sequence, confirms sequence identity with high confidence and can detect deamidation, oxidation, and truncation artifacts at sub-percent levels. This approach is not realistic for most labs without dedicated proteomics infrastructure, but it is the gold standard for confirming vendor CoA authenticity.

A simpler orthogonal check accessible to most biochemistry labs is size-exclusion HPLC (SE-HPLC) using a calibrated column. This separates monomers from dimers and higher aggregates by hydrodynamic radius, and its results are independent of RP-HPLC, meaning a batch that passes RP-HPLC purity but shows >5% high-molecular-weight material on SE-HPLC has an aggregation problem invisible to the first method. Aggregated recombinant GH not only has reduced potency but also elevated immunogenic potential in animal models, which can confound immune-response readouts.

Our supplier verification guide provides a step-by-step framework for requesting and evaluating CoA documentation from research-peptide vendors, including specific questions to ask about lot-specific versus representative CoA documents.

Dosage and Reconstitution, Research-Only Framing

Reconstitution procedure

Lyophilized somatropin requires careful reconstitution to preserve the native protein structure and biological activity. The general principles applicable to all reconstitution workflows are described in detail in the peptide reconstitution guide; the specific considerations for a 22 kDa globular protein like GH differ in several important respects from those for short synthetic peptides.

The preferred solvent for research-grade somatropin is bacteriostatic water (0.9% benzyl alcohol in sterile water for injection). Benzyl alcohol is not merely a preservative; it also reduces the surface-tension-driven interfacial denaturation that occurs when protein solutions contact hydrophobic surfaces or air bubbles. Sterile water for injection (without preservative) is an acceptable alternative when the reconstituted solution will be used within 24 hours, but multi-use vials should always use bacteriostatic water to extend in-use stability.

The reconstitution technique matters as much as solvent choice. The solvent should be directed against the inside wall of the vial and allowed to run down gently, not injected as a stream directly onto the lyophilized cake. The vial should then be swirled gently by rolling between the palms; it should never be vortexed, sonicated, or inverted repeatedly. Mechanical shear from these actions is a primary cause of interfacial aggregation and loss of biological activity. The solution should be clear to slightly opalescent after full dissolution; any visible particulates indicate aggregation and the batch should be discarded.

Worked reconstitution examples

Three worked examples at different target concentrations illustrate the reconstitution math relevant to a 36 IU vial:

Example 1, 2 IU/mL working stock. The 36 IU vial contains approximately 12 mg of somatropin (using a 3 IU/mg activity conversion). To produce a 2 IU/mL stock, add 18 mL of bacteriostatic water to yield 36 IU / 18 mL = 2 IU/mL, or equivalently 0.67 mg/mL. Each 0.1 mL aliquot delivers 0.2 IU. This is a dilute stock appropriate for cell-culture experiments where large volumes are manageable, but it requires substantial vial volume and may demand a 20 mL vial rather than the supplied container.

Example 2, 4 IU/mL working stock. Adding 9 mL of bacteriostatic water produces a 4 IU/mL (1.33 mg/mL) stock. Each 0.1 mL aliquot delivers 0.4 IU. This concentration is frequently referenced in literature-reported rat subcutaneous dosing protocols, where volume-per-dose constraints are tighter. A 100 g rat receiving 1 IU/kg/day (a common literature reference dose) would receive 0.1 mL per injection at this concentration.

Example 3, 6 IU/mL concentrated stock. Adding 6 mL of bacteriostatic water yields a 6 IU/mL (2.0 mg/mL) stock. Each 0.1 mL aliquot delivers 0.6 IU. This represents a pragmatic compromise between concentration and solubility; somatropin solutions above approximately 3-4 mg/mL begin to show increased aggregation propensity at refrigerator temperature, so 2 mg/mL is typically near the upper practical limit for research-grade preparations without specialty stabilizer formulations.

For detailed dose-volume calculation methodology including allometric scaling from human literature doses to rodent equivalents, see the dosage calculation guide.

Literature-reported research doses in preclinical models

In the published rat literature, somatropin research protocols have employed a range of doses depending on experimental context. Studies examining body composition endpoints in hypophysectomized rats typically use 1-2 IU/kg/day by subcutaneous injection, divided into one or two administrations to approximate the pulsatile GH secretory pattern. ^[13] Studies targeting bone growth plate effects in GH-deficient rodent models have used 3-5 IU/kg/day with DEXA-based endpoints at 4 and 8 weeks. Studies examining metabolic effects including lipolysis and insulin sensitivity in normal-weight rodents have used lower doses of 0.3-0.5 IU/kg/day to avoid pharmacological override of normal GH axis feedback. ^[15]

In cell culture, somatropin concentration ranges vary by cell type and endpoint. Hepatocyte IGF-1 gene expression studies typically use 100-1000 ng/mL (approximately 4.5-45 nM based on the 22,124 Da MW). Adipocyte lipolysis assays are frequently conducted at 10-100 ng/mL. Chondrocyte proliferation studies require 100-500 ng/mL to produce measurable mitogenic responses in a standard 48-hour assay window. These ranges should be confirmed against the specific cell line and passage number in pilot experiments before committing full reagent budgets.

Side Effects and Safety, Preclinical and Clinical Signal

Fluid retention and edema

Fluid retention is the most consistently reported adverse effect of supraphysiological GH exposure in clinical literature, and preclinical animal models recapitulate this finding. The mechanism involves GH-stimulated aldosterone secretion and direct GHR-mediated renal tubular sodium and water reabsorption, compounded by IGF-1-driven natriuretic peptide suppression. ^[14] In rat models receiving 3-5 IU/kg/day, measurable increases in tissue water content and body weight distinct from lean-mass accrual are detectable within 1-2 weeks. Researchers interpreting body-composition endpoints need to account for this fluid component, particularly in DEXA-based fat-free mass measurements.

Glucose metabolism and insulin resistance

GH exerts counter-regulatory effects on insulin signaling through multiple mechanisms: post-receptor inhibition of IRS-1 tyrosine phosphorylation, upregulation of gluconeogenic enzyme expression, and direct stimulation of pancreatic glucagon release. ^[11] In chronic high-dose animal protocols, frank insulin resistance is measurable by glucose tolerance testing within 4-6 weeks, and at very high doses (above 5 IU/kg/day in rodents) pancreatic beta-cell decompensation with hyperglycemia has been reported. Monitoring random blood glucose and terminal HOMA-IR measurement is advisable in any rodent study using GH above 1 IU/kg/day for more than 3 weeks.

GH-receptor downregulation and paradoxical effects

Chronic continuous GH exposure downregulates GHR expression and increases SOCS2-mediated receptor degradation, which can produce a paradoxical state of apparent GH resistance despite elevated circulating GH levels. ^[10] This is mechanistically distinct from GH deficiency but produces overlapping phenotypic features including reduced lean mass accretion in longer studies. Pulsatile GH administration patterns (once or twice daily injection rather than osmotic pump-driven continuous infusion) preserve receptor sensitivity more effectively and more closely replicate physiological GH secretion rhythms.

Immunogenicity considerations

Recombinant proteins can elicit anti-drug antibodies (ADAs) in animal hosts, and somatropin is no exception. In rodent studies lasting more than 4 weeks, a proportion of animals (estimated 5-15% in published studies using standard adjuvant-free protocols) will develop measurable binding antibodies. ^[7] These antibodies may be neutralizing or non-neutralizing; neutralizing ADAs effectively reduce the pharmacologically active GH concentration and will attenuate pharmacodynamic endpoints without reducing exogenous GH measurement by standard ELISA (which may not distinguish bound from free GH). Terminal blood collection with neutralization-assay testing is advisable in any chronic rodent study to allow post-hoc stratification of responders and non-responders.

Carcinogenicity considerations in rodent models

Chronic IGF-1 elevation is associated with increased cell-cycle entry in rapidly proliferating tissues. Long-term (>6 month) rodent studies with supraphysiological somatropin doses have identified increased polyp formation in colonic epithelium and accelerated mammary gland development in female rodents. ^[12] These effects are dose-dependent and are not consistently observed at doses that normalize rather than supraphysiologically elevate IGF-1. Researchers planning longevity or aging studies with chronic GH administration should include colorectal histopathology and, in female animals, mammary tissue examination in the study endpoint design.

How It Compares, HGH 191AA vs Related Research Compounds

Comparative interpretation

HGH 191AA Somatropin and its indirect axis-stimulating comparators occupy fundamentally different pharmacological positions that reflect the distinction between receptor-direct and secretagogue-mediated GH axis activation. Direct GHR agonism with somatropin bypasses the pituitary entirely, meaning that it can produce GH-driven effects in animals with pituitary damage, ablation, or dysfunction. This makes it the essential tool for experiments where pituitary sufficiency cannot be assumed or where endogenous GH pulsatility must be controlled rather than stimulated.

GHRH analogues (sermorelin, CJC-1295, tesamorelin) and GHSR agonists (ipamorelin, MK-677) work through the pituitary and therefore require intact hypothalamic-pituitary signaling to produce downstream GH release. Their advantage is a more physiological pulsatile GH secretory pattern and, for MK-677 specifically, oral bioavailability that simplifies chronic rodent dosing. However, they are unreliable in hypophysectomized models and produce more variable IGF-1 responses because the GH-pulse amplitude depends on endogenous pituitary reserve, which varies between individual animals. ^[9]

The immunogenicity comparison is worth examining carefully. Somatrem (Met-GH) accumulated a post-marketing safety signal regarding anti-GH antibody formation that contributed to its gradual displacement by somatropin in both clinical and research settings. ^[5] The 191AA (no N-terminal Met) sequence of somatropin represents a genuine immunogenicity advantage in longitudinal animal studies where ADA formation over multiple weeks could confound pharmacodynamic endpoints.

Where to Buy

Researchers seeking HGH 191AA Somatropin 36IU for laboratory applications can review our detailed vendor evaluation for Apollo Peptide Sciences on the product page for this specific lot. That page consolidates our CoA assessment, pricing history, and independent analytical commentary for this item.

For a broader comparison of research-peptide vendors assessed on criteria including cold-chain documentation, CoA completeness, third-party testing transparency, and order-fulfillment reliability, see our supplier directory and evaluation guide. Not all vendors who list somatropin at competitive prices provide lot-specific CoA documentation; the supplier guide includes a standardized checklist for assessing vendor documentation quality before purchasing recombinant protein for research use.

When evaluating pricing, consider the cost per IU rather than per vial. At $100.00 per 36 IU vial, the Apollo Peptide Sciences product prices at approximately $2.78/IU, which positions it competitively within the research-grade recombinant GH market. The 36 IU format provides more cost-effective per-IU pricing than smaller 10 IU or 12 IU vials while remaining practical for single-experiment runs without excessive long-term storage of reconstituted material.

FAQ

References